Cargando…
Cancer Treatment and Immunotherapy during Pregnancy
Background/aim: Immunotherapy has, in recent years, witnessed an expansion in its indications for the treatment of cancer. Coupled with the fact that, nowadays, even more women choose to postpone parenthood, thus increasing their chances of having some kind of malignancy during pregnancy, more and m...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611953/ https://www.ncbi.nlm.nih.gov/pubmed/36297515 http://dx.doi.org/10.3390/pharmaceutics14102080 |
_version_ | 1784819655847706624 |
---|---|
author | Koutras, Antonios Ntounis, Thomas Fasoulakis, Zacharias Papalios, Theodoros Pittokopitou, Savia Prokopakis, Ioannis Syllaios, Athanasios Valsamaki, Asimina Chionis, Athanasios Symeonidis, Panagiotis Samara, Athina A. Pagkalos, Athanasios Pergialiotis, Vasilios Theodora, Marianna Antsaklis, Panos Daskalakis, Georgios Kontomanolis, Emmanuel N. |
author_facet | Koutras, Antonios Ntounis, Thomas Fasoulakis, Zacharias Papalios, Theodoros Pittokopitou, Savia Prokopakis, Ioannis Syllaios, Athanasios Valsamaki, Asimina Chionis, Athanasios Symeonidis, Panagiotis Samara, Athina A. Pagkalos, Athanasios Pergialiotis, Vasilios Theodora, Marianna Antsaklis, Panos Daskalakis, Georgios Kontomanolis, Emmanuel N. |
author_sort | Koutras, Antonios |
collection | PubMed |
description | Background/aim: Immunotherapy has, in recent years, witnessed an expansion in its indications for the treatment of cancer. Coupled with the fact that, nowadays, even more women choose to postpone parenthood, thus increasing their chances of having some kind of malignancy during pregnancy, more and more women are eligible for receiving immunotherapy during this period of their lives. The cases of cancer diagnosed during pregnancy is an ever-increasing trend nowadays. Materials and methods: The oncologists and clinicians treating women often face a range of ethical and therapeutic dilemmas due to the particularity of the patient’s conditions. The primary concern is the protection of the mother, firstly, and then the fetus (through adjustments to the various treatment regimens) if possible. Results and conclusions: Oncological drugs, radiation therapy, surgery, or a combination of all the above methods are selected, depending on the case. In this project, we studied the oncology drugs used for various types of gestational cancer, their appropriateness and timing, as well as their possible effects on the parent and embryo upon their administration. Various studies have shown that the administration of oncological drugs should be postponed until at least after the first trimester of pregnancy. |
format | Online Article Text |
id | pubmed-9611953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96119532022-10-28 Cancer Treatment and Immunotherapy during Pregnancy Koutras, Antonios Ntounis, Thomas Fasoulakis, Zacharias Papalios, Theodoros Pittokopitou, Savia Prokopakis, Ioannis Syllaios, Athanasios Valsamaki, Asimina Chionis, Athanasios Symeonidis, Panagiotis Samara, Athina A. Pagkalos, Athanasios Pergialiotis, Vasilios Theodora, Marianna Antsaklis, Panos Daskalakis, Georgios Kontomanolis, Emmanuel N. Pharmaceutics Review Background/aim: Immunotherapy has, in recent years, witnessed an expansion in its indications for the treatment of cancer. Coupled with the fact that, nowadays, even more women choose to postpone parenthood, thus increasing their chances of having some kind of malignancy during pregnancy, more and more women are eligible for receiving immunotherapy during this period of their lives. The cases of cancer diagnosed during pregnancy is an ever-increasing trend nowadays. Materials and methods: The oncologists and clinicians treating women often face a range of ethical and therapeutic dilemmas due to the particularity of the patient’s conditions. The primary concern is the protection of the mother, firstly, and then the fetus (through adjustments to the various treatment regimens) if possible. Results and conclusions: Oncological drugs, radiation therapy, surgery, or a combination of all the above methods are selected, depending on the case. In this project, we studied the oncology drugs used for various types of gestational cancer, their appropriateness and timing, as well as their possible effects on the parent and embryo upon their administration. Various studies have shown that the administration of oncological drugs should be postponed until at least after the first trimester of pregnancy. MDPI 2022-09-29 /pmc/articles/PMC9611953/ /pubmed/36297515 http://dx.doi.org/10.3390/pharmaceutics14102080 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Koutras, Antonios Ntounis, Thomas Fasoulakis, Zacharias Papalios, Theodoros Pittokopitou, Savia Prokopakis, Ioannis Syllaios, Athanasios Valsamaki, Asimina Chionis, Athanasios Symeonidis, Panagiotis Samara, Athina A. Pagkalos, Athanasios Pergialiotis, Vasilios Theodora, Marianna Antsaklis, Panos Daskalakis, Georgios Kontomanolis, Emmanuel N. Cancer Treatment and Immunotherapy during Pregnancy |
title | Cancer Treatment and Immunotherapy during Pregnancy |
title_full | Cancer Treatment and Immunotherapy during Pregnancy |
title_fullStr | Cancer Treatment and Immunotherapy during Pregnancy |
title_full_unstemmed | Cancer Treatment and Immunotherapy during Pregnancy |
title_short | Cancer Treatment and Immunotherapy during Pregnancy |
title_sort | cancer treatment and immunotherapy during pregnancy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611953/ https://www.ncbi.nlm.nih.gov/pubmed/36297515 http://dx.doi.org/10.3390/pharmaceutics14102080 |
work_keys_str_mv | AT koutrasantonios cancertreatmentandimmunotherapyduringpregnancy AT ntounisthomas cancertreatmentandimmunotherapyduringpregnancy AT fasoulakiszacharias cancertreatmentandimmunotherapyduringpregnancy AT papaliostheodoros cancertreatmentandimmunotherapyduringpregnancy AT pittokopitousavia cancertreatmentandimmunotherapyduringpregnancy AT prokopakisioannis cancertreatmentandimmunotherapyduringpregnancy AT syllaiosathanasios cancertreatmentandimmunotherapyduringpregnancy AT valsamakiasimina cancertreatmentandimmunotherapyduringpregnancy AT chionisathanasios cancertreatmentandimmunotherapyduringpregnancy AT symeonidispanagiotis cancertreatmentandimmunotherapyduringpregnancy AT samaraathinaa cancertreatmentandimmunotherapyduringpregnancy AT pagkalosathanasios cancertreatmentandimmunotherapyduringpregnancy AT pergialiotisvasilios cancertreatmentandimmunotherapyduringpregnancy AT theodoramarianna cancertreatmentandimmunotherapyduringpregnancy AT antsaklispanos cancertreatmentandimmunotherapyduringpregnancy AT daskalakisgeorgios cancertreatmentandimmunotherapyduringpregnancy AT kontomanolisemmanueln cancertreatmentandimmunotherapyduringpregnancy |